MicroRNA controls malignancy and resistance of breast cancer cells

May 4, 2012

Many breast cancer patients are treated with a drug called tamoxifen. The substance blocks the effect of estrogen and thus suppresses the growth signals of this hormone in cancer cells. When resistance to the drug develops, tumor cells change their growth program: They change their behavior and shape, become more mobile and also adopt the ability to invade surrounding tissue. Scientists working with PD (Associate Professor) Dr. Stefan Wiemann of the German Cancer Research Center (DKFZ) have now also observed these changes in tamoxifen resistant breast cancer cells.

"Resistances to drugs are the main reason why therapies fail and disease progresses in many cancers," Wiemann explains. "We want to understand what goes on in the cells when this happens so we can develop better therapies in the future." Wiemann's co-worker, Dr. Özgür Sahin, suspects that tiny pieces of RNA known as microRNAs play a role in resistance development. "These minuscule RNA snippets control many cellular processes by attaching themselves to target gene transcripts and thus repressing protein production."

By treating cells in vitro with regular doses of tamoxifen, Sahin's team induced resistance of these cells to the drug. As resistance developed, the cancer cells switched to the development program that makes them grow even more invasively and more malignantly. Checking the complete spectrum of microRNAs in the resistant , the investigators noticed that production of microRNA 375 was more strongly reduced than others. When they boosted the production of microRNA 375, the cells started responding again to tamoxifen and switched back to their normal growth program. "This strongly suggests that a lack of microRNA 375 both increases malignancy and contributes to resistance development," says Özgür Sahin.

If microRNA 375 levels are low, increase the production of metadherin. Apparently, microRNA 375 suppresses the production of this cancer-promoting protein in healthy cells. In patients receiving tamoxifen therapy the team found that high metadherin levels in the go along with a high risk of recurrence. This suggests that microRNA 375 and metadherin are involved in the development of resistance to .

"The analysis of microRNAs in breast cancer has put us on the track of metadherin. We will possibly be able to specifically influence the cancer-promoting properties of this protein in the future," says Wiemann describing the goal of further research.

Explore further: No brakes on breast cancer cells

More information: Oncogene 2012, DOI: 10.1038/onc.2012.128

Related Stories

No brakes on breast cancer cells

December 16, 2011

Scientists of the German Cancer Research Center have discovered a tiny RNA molecule, called miR-520, which at once blocks two important pathways in the development of cancer in cells. In estrogen receptor-negative breast ...

Small molecules can starve cancer cells

October 9, 2011

All cells in our body have a system that can handle cellular waste and release building blocks for recycling. The underlying mechanism is called autophagy and literally means "self-eating". Many cancer cells have increased ...

Recommended for you

Study identifies genomic features of cervical cancer

January 23, 2017

Investigators with The Cancer Genome Atlas (TCGA) Research Network have identified novel genomic and molecular characteristics of cervical cancer that will aid in the subclassification of the disease and may help target therapies ...

Opinion: How dangerous is burnt toast?

January 23, 2017

A new campaign is warning people that burning some food, such as toast, is a potential cancer risk. Here, the evidence for this claim is explored by David Spiegelhalter, Professor of the Public Understanding of Risk at the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.